drugset / Trial / NCT04133337
Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC
Phase 1/2
Unknown
20 enrolled
Sichuan Cancer Hospital and Research Institute
Jiangsu HengRui Medicine Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The aim of this study was to investigate the safety and efficacy of SHR-1210 in combination with the anti-vascular survival target drug apatinib in patients with resectable NSCLC, and to provide new treatment options for neoadjuvant therapy in patients with the period IB-IIIA NSCLC.
Timeline
- Start
- 2019-11-01
- Primary completion
- 2020-06-01
- Completion
- 2021-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |